- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/575 - Hormones
Patent holdings for IPC class C07K 14/575
Total number of patents in this class: 1529
10-year publication summary
|
96
|
116
|
103
|
109
|
96
|
89
|
89
|
71
|
86
|
69
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novo Nordisk A/S | 2287 |
55 |
| Sanofi | 4089 |
30 |
| Eli Lilly and Company | 3878 |
29 |
| Zealand Pharma A/S | 259 |
25 |
| Janssen Pharmaceutica N.V. | 3369 |
23 |
| Protagonist Therapeutics, Inc. | 137 |
22 |
| Hanmi Science Co., Ltd. | 135 |
18 |
| The Regents of the University of California | 20059 |
15 |
| University of Miyazaki | 135 |
15 |
| H. Lundbeck A/S | 1250 |
15 |
| Dana-Farber Cancer Institute, Inc. | 2585 |
14 |
| Hanmi Pharm. Co., Ltd. | 574 |
14 |
| I2o Therapeutics, Inc. | 30 |
14 |
| The General Hospital Corporation | 4759 |
13 |
| Ip2ipo Innovations Limited | 172 |
13 |
| Centre National de La Recherche Scientifique | 10516 |
12 |
| Amgen Inc. | 4106 |
12 |
| Lipoxen Technologies Limited | 47 |
12 |
| President and Fellows of Harvard College | 5995 |
11 |
| University of Florida Research Foundation, Inc. | 4048 |
11 |
| Other owners | 1156 |